Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ (NCT06210854)
Double-Blind Randomized Phase II Clinical Trial Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ <CIN2
🩺 Plain-English Summary (8th-Grade Level)
This research is being done to test the safety and feasibility of an investigational DNA vaccine called pBI-11 and to find out what effects, if any, it has on women with persistent human papillomavirus 16 (HPV16+) and/or human papillomavirus (HPV18+) cervical infection. The DNA vaccine is designed to promote an immune response to treat disease caused by HPV types 16 and 18, viruses that can cause cervical cancer. The pBI-11 DNA vaccine or a placebo will be administered intramuscularly using the TriGridTM Delivery System.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- Johns Hopkins University — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (410) 955-8240
Email: klevins1@jhmi.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HPV Infection
- Intradermal, Fractional Dose of HPV Vaccines: — Seattle, Washington
- Immunogenicity of Fractional Dose of the HPV Vaccines — Seattle, Washington
- An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen — Boston, Massachusetts
- Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV — Rockville, Maryland
- Feasibility of HPV Testing With Mail-delivered Sample Collection Kits — San Francisco, California
- PCOM2 - The Physician Communication Intervention, Version 2.0 — Aurora, Colorado
Explore by condition: All HPV Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.